HRT in Australia: Is Hormone Replacement Therapy Right for You?
%20Medium.jpeg)
HRT works by replacing the hormones that the body produces less of during and after the menopausal transition. The primary hormone replaced is oestrogen, which declines as the ovaries gradually stop functioning. For women who still have a uterus, a progestogen (either natural progesterone or a synthetic progestin) is added to protect the uterine lining from the effects of unopposed oestrogen.
The rationale is straightforward. Many menopause symptoms, including hot flushes, night sweats, vaginal dryness, sleep disturbance, and mood changes, are driven by falling oestrogen levels. By restoring oestrogen to a level that alleviates symptoms, HRT can help manage these effects and improve quality of life.
According to Healthdirect Australia, HRT remains the most effective treatment for vasomotor symptoms (hot flushes and night sweats) and is also effective for preventing bone loss that accelerates after menopause. The Royal Australian College of General Practitioners (RACGP) supports the use of HRT in appropriate candidates, particularly when initiated within 10 years of menopause onset or before the age of 60.
It is worth understanding that HRT is not a one-size-fits-all treatment. The type of HRT, the dose, the delivery method, and the duration of use are all decisions that should be made in consultation with a doctor who understands your individual health history.
There are several forms of HRT prescribed in Australia, and the right choice depends on a range of factors, including whether a woman has had a hysterectomy, her symptom profile, her medical history, and her personal preferences.
Oestrogen-Only HRT
This is prescribed for women who have had a hysterectomy and no longer have a uterus. Because there is no uterine lining to protect, oestrogen can be given on its own. It is available as oral tablets, transdermal patches, gels, and sprays.
Combined HRT (Oestrogen + Progestogen)
For women who still have a uterus, a progestogen must be included alongside oestrogen. This can be taken continuously (both hormones every day, which typically results in no periods) or sequentially (oestrogen every day with progestogen added for 12 to 14 days each month, which typically produces a withdrawal bleed). The choice between continuous and sequential depends on where a woman is in her menopausal transition. Sequential is generally used during perimenopause, while continuous combined HRT is more commonly prescribed after menopause is established.
Delivery Methods
The delivery method matters and can influence both effectiveness and risk profile.
Oral tablets. These are the most commonly prescribed form of HRT in Australia. They are convenient and well studied. However, oral oestrogen passes through the liver, which can increase the production of clotting factors. For women with risk factors for blood clots (including obesity, smoking, or a history of venous thromboembolism), non-oral routes may be preferred.
Transdermal patches. Patches deliver oestrogen through the skin, bypassing the liver. Research published in The BMJ suggests that transdermal oestrogen is associated with a lower risk of venous thromboembolism compared to oral forms. Patches are typically applied to the lower abdomen or buttock and changed once or twice a week.
Gels and sprays. Topical oestrogen gels (such as Estradot and Sandrena) and sprays are applied to the skin daily. Like patches, they avoid first-pass liver metabolism and may be preferable for women with certain risk factors.
Vaginal oestrogen. Low-dose vaginal oestrogen (available as creams, pessaries, or a vaginal ring) is prescribed specifically for urogenital symptoms such as vaginal dryness, discomfort during intercourse, and recurrent urinary tract infections. Vaginal oestrogen acts locally, with minimal systemic absorption. The Australasian Menopause Society notes that vaginal oestrogen is safe for long-term use and can be used alongside systemic HRT if needed.
Bioidentical and Compounded Hormones
There is growing public interest in "bioidentical" hormones. It is important to distinguish between regulated bioidentical hormones (such as micronised progesterone, which is TGA-approved and available on prescription in Australia) and compounded bioidentical hormones, which are custom-mixed by compounding pharmacies. The RACGP and the Australasian Menopause Society advise caution with compounded preparations, as they are not subject to the same quality controls and consistency testing as TGA-approved products. Regulated bioidentical HRT is a legitimate and evidence-based option. Compounded preparations should be discussed with a doctor who can weigh the evidence and alternatives.
HRT may be suitable for women experiencing moderate to severe menopausal symptoms that are affecting their quality of life. The Australasian Menopause Society's position statement identifies the following groups who may benefit.
Women with significant vasomotor symptoms. Hot flushes and night sweats are the most common reason women seek HRT. For many, these symptoms are not merely uncomfortable but genuinely debilitating, disrupting sleep, work, and daily functioning.
Women experiencing urogenital symptoms. Vaginal dryness, painful intercourse, and recurrent urinary tract infections related to menopause can be effectively treated with local vaginal oestrogen, which is considered low-risk even for women who may not be candidates for systemic HRT.
Women at increased risk of osteoporosis. Oestrogen plays a critical role in maintaining bone density. After menopause, bone loss accelerates significantly. HRT has been shown to reduce fracture risk, and the Australasian Menopause Society supports its use for bone protection in women under 60 or within 10 years of menopause onset.
Women who experience early menopause. Women who go through menopause before the age of 45 (whether naturally, surgically, or due to medical treatment) are generally advised to use HRT at least until the average age of natural menopause (51 years) to mitigate the cardiovascular and bone health risks associated with premature oestrogen deficiency. This guidance is supported by the Australasian Menopause Society and the RACGP.
Who Should Exercise Caution
HRT is not appropriate for everyone. Women with a history of oestrogen-receptor-positive breast cancer, active liver disease, unexplained vaginal bleeding, or a history of blood clots may need to explore alternative treatments. These decisions require an individualised risk-benefit discussion with a qualified clinician.
The conversation about HRT risks changed dramatically in 2002, when the Women's Health Initiative (WHI) study reported increased risks of breast cancer, heart disease, stroke, and blood clots in women taking combined HRT. The findings led to a sharp decline in HRT prescribing worldwide.
In the years since, extensive reanalysis of the WHI data and additional research have provided a far more nuanced picture. The key findings that have shaped current Australian clinical practice include the following.
The timing hypothesis. Research published in the New England Journal of Medicine and subsequent analyses by the Australasian Menopause Society support the "timing hypothesis," which holds that HRT initiated within 10 years of menopause onset or before the age of 60 carries a favourable benefit-risk profile. When started in this window, HRT may even offer cardiovascular protection. The risks identified in the original WHI study were primarily seen in women who were significantly older (average age 63) at the time they began HRT.
Breast cancer risk in context. The absolute increase in breast cancer risk associated with combined HRT is small. A 2019 meta-analysis published in The Lancet estimated that five years of combined HRT starting at age 50 was associated with approximately one additional case of breast cancer per 50 women over a 20-year follow-up period. Oestrogen-only HRT (used by women without a uterus) was associated with little to no increased breast cancer risk. The RACGP advises that this risk should be weighed against the benefits and compared to other lifestyle factors that carry similar or greater risk, such as alcohol consumption and obesity.
Blood clot risk varies by delivery method. As noted above, transdermal oestrogen appears to carry a lower risk of venous thromboembolism compared to oral oestrogen. This has led many Australian clinicians to favour patches and gels, particularly for women with additional risk factors.
Bone protection. HRT is effective at preventing osteoporotic fractures. A systematic review published in the Cochrane Database found that HRT significantly reduced the incidence of hip, vertebral, and other fractures.
Common Side Effects
When starting HRT, some women experience side effects that typically settle within the first three months. These may include breast tenderness, bloating, headaches, nausea (more common with oral forms), and irregular bleeding or spotting. If side effects persist, adjusting the type, dose, or delivery method often resolves them. This is another reason why ongoing follow-up with a GP is valuable.
In Australia, HRT is a prescription medication. It requires a consultation with a registered medical practitioner who can assess your symptoms, review your medical history, and determine whether HRT is appropriate for your circumstances.
Traditionally, this meant booking an in-person appointment, which could involve waiting weeks for availability, especially in regional and rural areas. Online consultations have made this process more accessible.
Here is how the process typically works when seeking menopause HRT through an online-first clinic.
Step one: Book an appointment. Most online clinics allow patients to book either a scheduled appointment at a preferred time or join a first-available queue for more immediate access.
Step two: Complete a health assessment. Before the consultation, patients typically provide information about their symptoms, medical history, current medications, and any relevant family history. This allows the clinician to prepare and make the most of the consultation time.
Step three: Video consultation. The appointment takes place via video call with a registered Australian GP. The doctor will discuss your symptoms, review your history, answer your questions, and determine whether HRT is appropriate. If so, they will discuss the type, dose, and delivery method that best suits your situation.
Step four: Prescription and follow-up. If HRT is prescribed, the prescription is sent electronically. Follow-up appointments are scheduled to monitor how you are responding and make adjustments if needed.
It is worth emphasising that HRT prescribing should always involve a proper clinical assessment. A responsible online clinic will take the same care with history-taking, risk assessment, and ongoing monitoring as an in-person practice. The delivery method is different, but the clinical standard should not be.
Abby Health is Australia's largest online-first clinic, and menopause care is one of the areas where the model makes a real difference. For many women, accessing a GP who has time to discuss HRT properly has become increasingly difficult. Short appointment slots, long wait times, and the challenge of finding a doctor who is up to date on the latest menopause evidence all create barriers.
At Abby Health, consultations are available seven days a week, 365 days a year, with a care network of over 300 clinicians. Patients can book a scheduled appointment with a preferred doctor or use the first-available queue for same-day access when the need is more urgent.
One of the things that makes a difference for menopause care specifically is continuity. HRT often requires adjustments over the first few months: changes in dose, switching delivery methods, or adding a different progestogen. Having a GP who knows your history and understands what has already been tried saves time and avoids the frustration of repeating your story to a different doctor each visit. Abby Health's 71% rebook rate means that three in four patients see the same doctor again, which is the kind of continuity that matters when managing an ongoing treatment like HRT.
Behind every consultation, Abby AI (Abby Health's medical AI) works as a clinical decision-support tool, surfacing relevant patient history, symptoms, and risk signals so that clinicians start each appointment informed. It never diagnoses or prescribes. It simply ensures the doctor has the full picture before the conversation begins.
Consultations are bulk billed for eligible patients, removing the cost barrier that prevents many Australians from seeking the care they need. Whether you are in Sydney, rural Queensland, or anywhere else in Australia, the same clinical standard applies.
If you are experiencing menopause symptoms and want to discuss whether HRT might be appropriate, booking a consultation is straightforward. You can start at abbyhealth.com.au.
Is HRT safe? For most women under 60, or within 10 years of menopause onset, the benefits of HRT generally outweigh the risks. The safety profile depends on the type of HRT, the delivery method, and individual health factors. A thorough discussion with your GP is the best way to understand your personal risk-benefit balance.
How long can I take HRT? There is no fixed time limit. Current guidance from the Australasian Menopause Society recommends reviewing HRT annually with your GP. Many women use HRT for five to ten years, and some continue longer if the benefits outweigh the risks. The decision to continue or stop should be made collaboratively with your doctor.
Will I gain weight on HRT? Weight gain during menopause is common and is primarily related to ageing, metabolic changes, and reduced physical activity rather than HRT itself. Some research suggests that HRT may actually help reduce the redistribution of fat to the abdomen that occurs after menopause.
Can I get HRT if I have a family history of breast cancer? A family history of breast cancer does not automatically rule out HRT, but it does require careful risk assessment. Your GP may recommend additional screening or suggest alternative treatments depending on the specifics of your family history. This is exactly the kind of decision that benefits from a detailed consultation.
Is there a difference between bioidentical and conventional HRT? Regulated bioidentical hormones (such as micronised progesterone and oestradiol) are TGA-approved and widely prescribed in Australia. They are chemically identical to hormones the body produces naturally. The key distinction is between regulated bioidentical products and compounded preparations, which are not subject to the same quality controls. Discuss both options with your doctor.
Do I need blood tests before starting HRT? In most cases, the diagnosis of menopause is made clinically, based on symptoms and age, and blood tests are not required. However, blood tests may be useful in certain situations, such as suspected premature menopause (under 45) or when the clinical picture is unclear. Your GP will advise whether testing is appropriate.
Can I start HRT during perimenopause? Yes. HRT can be started during perimenopause to manage symptoms. Sequential combined HRT (oestrogen daily with progestogen added cyclically) is typically used during this phase, as it accommodates the possibility of ongoing natural cycles.
Editorial Standards
Notice something that doesn’t look right? Let us know at support@abbyhealth.app
Authors
.avif)
